Cognivue, Inc.

Why use digital cognitive assessments? Dr. Diego Cahn-Hidalgo had this to say: "Prior to having digital cognitive assessments I used to use all the different tests that I possibly get my hands on. . . . The problem with some of those tests is when I don't do it myself . . . there's different people who do different slight variations on how to score things. And so the reliability of some of those tests became, you know, sometimes a little nebulous. . . . To me, digital assessment is so valuable because it's so reliable and the retest capabilities of it is so good." Dr. Diego Cahn-Hidalgo, Practicing Clinical Professor of Medicine at Internal Medicine of Brighton was a participant in a Cognivue, Inc. and marcus evans Group webinar. View the webinar: https://bit.ly/4fnS45f Using digital cognitive assessment tools like Cognivue Clarity and Cognivue Thrive for early detection of cognitive changes allows individuals to address modifiable risk factors sooner, potentially changing the course of cognitive decline. #brainhealth #cognitivefunction #dementia #modifiableriskfactors #prevention #Cognivue

Sleep and Relax (#tiptuesday)! Insufficient sleep can not only make a person irritable, but it can also affect memory and decision making. Healthy adults need between 7 and 9 hours of sleep per night. #modifiableriskfactor #prevention #healthandwellness #lifestyle #brainhealth #cognitivescreening #Cognivue

“I'm very passionate about telling every provider that dementia care is their business. Most of our patients are going to, you know, if they're lucky, live past the age of 65. And a large proportion of them, as they live longer, will have some cognitive impairment. So I think this conversation is within everyone's scope of practice, and it will absolutely affect adherence and care in every setting.” Part of the panelist conversation with Dr. Ruth Morin, Ph.D., Neuropsychologist & Dementia Researcher, Hoag Memorial Hospital Presbyterian. Excerpt from the webinar “Raising the Importance of Primary Dementia Prevention: A Panel Discussion.” Watch the full webinar here: https://bit.ly/3D6DbHn At Cognivue, Inc., our mission is to provide cognitive assessment tools to a broad range of healthcare providers for the early detection of cognitive impairment. Early detection allows patients to address modifiable risk factors sooner, potentially changing the course of cognitive decline. #dementia #alzheimersdisease #modifiableriskfactors #prevention #brainhealth #reducetherisk #takeaction #consultation #scopeofpractice

Spotted! Cognivue Clarity was featured in a ABC7 SWFL cover story titled, “Gulf Coast dementia cases climbing; how new tech can help you stay ahead.” Dr. Thomas Felke explains, “The machine is really designed for an individual to track and take control of their cognitive health. It’s not unlike how we do it every year when we go for our annual vision screening or how we would potentially do blood pressure screenings.” Read or watch it here: https://bit.ly/3ZySwb2 As shared by Cognivue, Inc. President, Paul W. Estes, “For 15 years, my passion with Cognivue has been to empower healthcare professionals with innovative tools to assess cognitive function quickly and accurately. Together, we can take proactive steps towards better brain health and a brighter future.” Cognivue Clarity, a 10-minute digital cognitive assessment tool, is intended to aid licensed clinicians in the assessment of cognitive function. Contact us to find out more: info@cognivue.com. #cognitivescreening #earlydetection #brainhealth #abc7 #swfl #cognivue

Cognivue, Inc. is pleased to have collaborated with the Milken Institute Alliance to Improve Dementia Care on their latest report, Improving Early Detection of Cognitive Impairment and Dementia! This report presents the latest insights, innovations, and scalable solutions to enhance early detection of mild cognitive impairment and dementia across healthcare and community settings. Developed with input from Alliance members, expert interviews, a multisector roundtable, and extensive research, the report outlines five recommendations centered around two themes: 1) Improving primary care capacity and workflows 2) Expanding detection efforts beyond primary care Read the full report here: https://lnkd.in/eRMHTdQQ #EarlyDetection #Dementia #AlzheimersDisease #BrainHealth

Research has shown that early detection and people taking action when it matters most can prevent, delay, or slow the onset of cognitive decline [1]. The Lancet Commission reported that 45% of the risk factors for dementia can be modified with lifestyle changes [2]. Let’s all do our part to advocate for how important it is for individuals to adopt a combination of key healthy lifestyle habits, develop good awareness of overall wellness, and optimize their cognition by taking early and proactive steps that may help reduce the risk of memory loss and other forms of cognitive decline [3]. Using cognitive assessment tools like Cognivue Clarity and Cognivue Thrive for early detection of cognitive changes allows individuals to address modifiable risk factors sooner, potentially changing the course of cognitive decline. #earlydetectionmatters #cognitivescreening #brainhealth #modifiableriskfactors #takeaction #cognivue References: [1] Reducing Risk of Alzheimer’s Disease. (2022, September 13). Centers for Disease Control and Prevention. https://bit.ly/3OMCoh1 [2] Livingston G, Huntley J, Liu K, et al. (2024). Dementia Prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 404(10452), 572-628. DOI: 10.1016/S0140-6736(24)01296-0. https://bit.ly/49xJUG7 [3] Dementia. (2022, September 20). Retrieved November 20, 2022, from https://bit.ly/3P97YWN.

“I think that people are starting to appreciate more and more there are things they can do—that's good that reduces stigma—but they still need some guidance as to what have brain healthy lifestyle might look like.” Quote from Dr. Sharon Cohen, Medical Director & Principal Investigator, Toronto Memory Program. Excerpt from our September webinar titled “Raising the Importance of Primary Dementia Prevention: A Panel Discussion.” Watch the full webinar here: https://bit.ly/49lf6IN Cognivue, Inc.’s mission is to advance early detection of cognitive impairment in order to address modifiable risk factors sooner which could potentially change the course of cognitive decline. #dementia #alzheimersdisease #modifiableriskfactors #prevention #brainhealth #reducetherisk #takeaction

Optimal Vision (#tiptuesday)! Research has found the relationship between cognitive decline and vision impairment may be a modifiable risk factor [1]. To manage or prevent vision impairment, schedule regular visits with your vision healthcare provider. #modifiableriskfactor #prevention #healthandwellness #lifestyle #brainhealth #cognitivescreening #Cognivue Reference: 1. Hajek A et al. Effect of visual impairment on physical and cognitive function in old age: findings of a population-based prospective cohort study in Germany. J Am Ger Soc. 2016;64(11):2311- 2316.

Article published last month in Scientific Reports demonstrates Cognivue Clarity’s ability to reliably differentiate between the cognitively normal, mild cognitive impairment (MCI), and mild dementia groups regardless of amyloid status. Main Takeaways: ➡️ Cognivue Clarity reliably detected cognitive impairment in clinical and biomarker-confirmed samples. ➡️ Cognivue Clarity differentiated between cognitively normal, MCI, and dementia groups regardless of amyloid status. ➡️ With support of statistically significant findings—Cognivue Clarity captured most individuals with cognitive impairment, and excluded most individuals who are cognitively normal—Cognivue Clarity can provide useful information for consideration for further evaluation with biomarkers and detailed neuropsychological evaluation. ➡️ Cognivue Clarity’s ability to differentiate MCI due to AD from AD, and between AD and non-AD forms of impairment has value to clinical research and real-world practice as AD treatments move to a more precision-based approach where differential treatment options (pharmacologic and non-pharmacologic) may require such distinction. Read it here: https://lnkd.in/eddUPM8z Data comes from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation. #alzheimersdisease #amyloid #mildcognitiveimpairment #dementia #cognitivehealth #biohermes #earlydetection #cognivue Cognivue, Inc.

When asked about how he hopes the Bio-Heremes-002 study will impact the future, Dr. Ernest Fung, PsyD, ABPP-CN, Senior Vice President of Clinical and Medical Affairs at Cognivue, Inc. had the following to share: “I think what is really going to be important, this study is going to provide valuable data that I believe will streamline future diagnostic and assessment process. And together, with data coming from a diverse subject group, I think it will help us to make dementia diagnosis more accessible—not just from a practical standpoint, but from a financial standpoint—serving to increase health equity for different populations.” Cognivue recently announced a strategic partnership with the Global Alzheimer's Platform Foundation (GAP) as we participate in the Bio-Hermes-002 clinical trial study with the Congivue Clarity device. Cognivue Clarity is a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence effectively and efficiently in 10 minutes. #BioHermes002 #BioHermes #StopALZ #Alzheimersdisease #cognitiveassessment #accessibility #digitalbiomarker #cognivue